All About Multiple Sclerosis

More MS news articles for October 2003

Cardinal/InChord partnership to market spine drug

September 26, 2003
Colombus Business First

Rxpedite, a partnership between Cardinal Health Inc. and InChord Communications, will market an experimental drug for spinal cord injury and multiple sclerosis.

The partnership was hired by Acorda Therapeutics, a privately held drug researcher based in Hawthorne, N.Y., to market Fampridine-SR. Fampridine-SR is in clinical trials with the Food and Drug Administration.

Cardinal Health, a Dublin-based provider of goods and services to the health-care industry, would distribute the drug through its sales network if it is approved by the FDA. InChord, a Westerville-based marketing company focused on the health care market, would market and advertise the drug.

Copyright © 2003, American City Business Journals Inc.